(ORKA) Oruka Therapeutics - Ratings and Ratios
Monoclonal, Antibodies, Psoriasis, Inflammatory, Immunology
Description: ORKA Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel monoclonal antibody therapeutics for the treatment of psoriasis and other inflammatory and immunology indications. The companys pipeline includes several promising candidates, including ORKA-001, which targets the p19 subunit of interleukin-23, and ORKA-002, which targets interleukin-17A and interleukin-17F. These therapies have the potential to provide innovative treatment options for patients with moderate to severe psoriasis and other related conditions.
The companys lead products are in various stages of clinical development, with ORKA-001 currently in Phase 1 trials for the treatment of psoriasis. ORKA-002 is also being developed for the treatment of psoriatic arthritis and other conditions. Additionally, Oruka Therapeutics is exploring a sequential combination regimen, ORKA-021, which combines ORKA-002 and ORKA-001. The companys research and development efforts are focused on addressing the complex biology underlying inflammatory and immunology disorders.
From a technical analysis perspective, the stock has shown significant volatility, with an Average True Range (ATR) of 0.80, representing a 6.88% daily price movement. The current price of $11.68 is below the 20-day Simple Moving Average (SMA) of $11.99, indicating a potential downward trend. However, the stock is above the 50-day SMA of $10.56, suggesting some underlying strength. Given the current technical indicators and fundamental data, including a market capitalization of $888.26M, we can forecast that the stock may experience a short-term correction, potentially testing the $10.56 level, before resuming its upward trajectory, driven by progress in its clinical trials and pipeline development.
Based on the available data, a potential forecast for Oruka Therapeutics, Inc. (ORKA) could be that the stock will experience a short-term decline to around $10.50, followed by a rebound to $14.00, driven by positive developments in its clinical trials and the overall growth of the biopharmaceutical industry. This forecast is based on a combination of technical analysis, including the stocks current price and moving averages, as well as fundamental data, including the companys market capitalization and pipeline development.
ORKA Stock Overview
| Market Cap in USD | 592m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1997-08-08 |
ORKA Stock Ratings
| Growth Rating | -32.4% |
| Fundamental | 19.8% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -48.3% |
| Analyst Rating | 4.88 of 5 |
ORKA Dividends
Currently no dividends paidORKA Growth Ratios
| Growth Correlation 3m | 81.8% |
| Growth Correlation 12m | -50.5% |
| Growth Correlation 5y | -45.3% |
| CAGR 5y | 0.72% |
| CAGR/Max DD 3y | 0.01 |
| CAGR/Mean DD 3y | 0.03 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.01 |
| Beta | 0.979 |
| Volatility | 65.44% |
| Current Volume | 132.9k |
| Average Volume 20d | 122.9k |
| Stop Loss | 13.8 (-7.4%) |
| Signal | -1.02 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-100.0m TTM) > 0 and > 6% of Revenue (6% = -6.00m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA 16.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 (>3.0%) and CFO -97.7m > Net Income -100.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 27.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.2m) change vs 12m ago 191.1% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -51.09% (prev 0.0%; Δ -51.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -197.3 (EBITDA TTM -99.4m / Interest Expense TTM 504.0k) >= 6 (WARN >= 3) |
Altman Z'' -8.58
| (A) 0.90 = (Total Current Assets 332.0m - Total Current Liabilities 12.1m) / Total Assets 357.4m |
| (B) -0.36 = Retained Earnings (Balance) -129.3m / Total Assets 357.4m |
| (C) -0.51 = EBIT TTM -99.5m / Avg Total Assets 195.6m |
| (D) -9.38 = Book Value of Equity -129.3m / Total Liabilities 13.8m |
| Total Rating: -8.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.76
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -21.84% = -5.0 |
| 3. FCF Margin -58.06% = -7.50 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -37.64)% = -12.50 |
| 7. RoE -27.91% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend 45.19% = 2.26 |
What is the price of ORKA shares?
Over the past week, the price has changed by +2.79%, over one month by +6.30%, over three months by +35.42% and over the past year by -38.76%.
Is Oruka Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ORKA is around 14.08 USD . This means that ORKA is currently overvalued and has a potential downside of -5.5%.
Is ORKA a buy, sell or hold?
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ORKA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.5 | 165.1% |
| Analysts Target Price | 39.5 | 165.1% |
| ValueRay Target Price | 15.9 | 6.5% |
Last update: 2025-09-10 04:44
ORKA Fundamental Data Overview
CCE Cash And Equivalents = 328.4m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -100.0m + Cost of Revenue 31.0k = -99.9m USD
Beta = None
Revenue TTM = -99.9m USD
EBIT TTM = -99.5m USD
EBITDA TTM = -99.4m USD
Long Term Debt = 1.67m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 660.0k USD (from shortTermDebt, last quarter)
Debt = 2.33m USD (Calculated: Short Term 660.0k + Long Term 1.67m)
Net Debt = -63.1m USD (from netDebt column, last quarter)
Enterprise Value = 265.6m USD (591.7m + Debt 2.33m - CCE 328.4m)
Interest Coverage Ratio = -197.3 (Ebit TTM -99.5m / Interest Expense TTM 504.0k)
FCF Yield = -21.84% (FCF TTM -58.0m / Enterprise Value 265.6m)
FCF Margin = -58.06% (FCF TTM -58.0m / Revenue TTM -99.9m)
Net Margin = -100.0% (Net Income TTM -100.0m / Revenue TTM -99.9m)
Gross Margin = -100.0% ((Revenue TTM -99.9m - Cost of Revenue TTM 31.0k) / Revenue TTM)
Tobins Q-Ratio = -2.05 (set to none) (Enterprise Value 265.6m / Book Value Of Equity -129.3m)
Interest Expense / Debt = 21.67% (Interest Expense 504.0k / Debt 2.33m)
Taxrate = 21.0% (US default)
NOPAT = -99.5m (EBIT -99.5m, no tax applied on loss)
Current Ratio = 27.42 (Total Current Assets 332.0m / Total Current Liabilities 12.1m)
Debt / Equity = 0.01 (Debt 2.33m / last Quarter total Stockholder Equity 343.6m)
Debt / EBITDA = -0.02 (Net Debt -63.1m / EBITDA -99.4m)
Debt / FCF = -0.04 (Debt 2.33m / FCF TTM -58.0m)
Total Stockholder Equity = 358.2m (last 4 quarters mean)
RoA = -27.97% (Net Income -100.0m, Total Assets 357.4m )
RoE = -27.91% (Net Income TTM -100.0m / Total Stockholder Equity 358.2m)
RoCE = -27.63% (Ebit -99.5m / (Equity 358.2m + L.T.Debt 1.67m))
RoIC = -27.99% (NOPAT -99.5m / Invested Capital 355.3m)
WACC = 9.65% (E(591.7m)/V(594.0m) * Re(9.62%)) + (D(2.33m)/V(594.0m) * Rd(21.67%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.92 | Cagr: 38.22%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -58.0m)
EPS Correlation: 45.19 | EPS CAGR: 77.22% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for ORKA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle